Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I sold yesterday. Made nice profits! Keeping on my radar for any new developments.
Biden's Border Policies Are Reckless: I’m Fighting Back, but I Need Your Help. Donate Now! Don’t Take The Corporate Media’s Bait: They Just Want to Divide The GOP. Donate Now. Fight For Freedom. We Need Your Support. Don’t Let The Media Win. Fight The Liberal Machine. Become A DeSantis Donor. Make An Impact. Fight Back Against Biden. Back Florida’s Governor. Join The Fight.
NVIV Shares Resume Trading Following Circuit Breaker Halt. Up 64% today.
Chevron refinery production in Venezuela translates into revenues. Although this is a gamble in dealing with a dictator socialist regime. Retooling and start-up costs for a refinery runs into multimillion dollars.
Chevron refinery production in Venezuela translates into revenues. Although this is a gamble in dealing with a dictator socialist regime. Retooling and start-up costs for a refinery runs into multimillion dollars.
Venezuela sour crudes are heavy in sulfur content, requiring additional refining that typically needs natural gas, which has doubled in price this year. If the crude is not used, it could end up being stored in oil tanks or exported away and may not have the intended effect of reducing gasoline prices.
Venezuela sour crudes are heavy in sulfur content, requiring additional refining that typically needs natural gas, which has doubled in price this year. If the crude is not used, it could end up being stored in oil tanks or exported away and may not have the intended effect of reducing gasoline prices.
Nice volume! Tutes, mutual funds, University endowment funds, and pension funds are all buying their initial shares today, and going forward.
BHVN
LMAO! Well go ahead and import oil from Venezuela! Maybe Biden can get you a job working for Pete Buttegeg in the Tranny Dept.
Obviously you lack understanding, similar to Biden’s cognitive issues. The rest of the folks here understand that with USA exporting oil & nat gas, tens of thousands of jobs are created here in USA.
USA is sitting on several hundred year supply of natural gas and crude oil. USA needs a president that will enable our country to be the #1 petroleum exporter of supply to the world.
BHVN is a great $$$$$ opportunity.
$15.00+ by closing bell Friday !
Multitude of positive catalysts: " Broad therapeutic research and development portfolio includes more than 13 clinical and pre-clinical programs with a focus on neuroscience and rare disorders including epilepsy, pain and mood disorders, obsessive compulsive disorder (OCD), spinocerebellar ataxia (SCA) and spinal muscular atrophy (SMA).
Excitement mounting for clinical stage neuroscience program in Kv7 Ion Channel Modulation which targets key subunits involved in neuronal signaling and plays a critical role in regulating the hyperexcitable state in epilepsy and potentially other central nervous system (CNS) disorders.
Biohaven retains Board and key management team with established legacy of bringing the market-leading medicine Nurtec® ODT (rimegepant) to patients; Names Bruce Car, Ph.D. as Chief Scientific Officer; Irfan Qureshi, M.D. as Chief Medical Officer; and Tanya Fischer, M.D., Ph.D. as Chief Development Officer and Head of Translational Medicine.
NEW HAVEN, Conn., Oct. 4, 2022 /PRNewswire/ -- Biohaven Ltd. (NYSE: BHVN) launched today as a new publicly traded company focused on delivering innovative life-changing treatments for neurological and neuropsychiatric diseases, including rare disorders, leveraging its proven drug development capabilities and proprietary technology platforms to advance a pipeline of best-in-class therapies. As of today, Biohaven has officially begun operating as a separate independent entity as part of the acquisition agreement with Pfizer in May 2022. The company, led by Vlad Coric, M.D. as Chairman and Chief Executive Officer, launched with approximately $257.8 million in cash at the distribution and no debt."
62nd HR ball has $2 million offer. Judge hit his 62nd home run in Game 2 of the Yankees’ doubleheader against the Rangers at Choctaw Stadium, and a lucky fan named Cory Youmans came away from the ball.
MORE ON:
AARON JUDGE
Aaron Judge gets rest day in season finale after hitting historic homer
Aaron Judge’s 62nd home run ball already has a $2 million offer
Aaron Judge’s historic 62nd home run in photos
Shop Aaron Judge jerseys on Amazon to celebrate his record-setting 62nd homer
As he was whisked around the stadium by security, Youmans was peppered with questions by reporters.
Asked what he was going to do with the ball, Youmans said, “That’s a good question! I haven’t thought about it!”
Upon a followup question where he was asked if he was going to keep the ball or give it back to Judge, Youmans, who was sporting a Texas Rangers cap, appeared to answer, “I don’t know.”
Pfizer acquired all of the outstanding shares of Biohaven not already owned by Pfizer for $148.50 per share in cash, for a total transaction consideration of approximately $11.6 billion. As a result of the acquisition, Biohaven became a wholly-owned subsidiary of Pfizer.
Effective immediately prior to the closing of the acquisition, Biohaven completed the spin-off of Biohaven Ltd. (NYSE: BHVN), distributing Biohaven Ltd.’s shares to Biohaven’s shareholders. Biohaven Ltd., a new company that retained Biohaven’s non-CGRP development stage pipeline compounds, holds the Kv7 ion channel activators, glutamate modulation, and myostatin inhibition platforms, preclinical product candidates, and certain corporate infrastructure assets excluded from the Pfizer acquisition. Pfizer, a Biohaven shareholder, received a pro rata portion of Biohaven Ltd.’s shares in the distribution and owns approximately 3% of Biohaven Ltd. Biohaven Ltd. will continue to trade on the New York Stock Exchange under the ticker "BHVN".
CNTQ & BHVN > both moving up this afternoon!
New name > Biohaven Ltd.
BHVN up 39% @ 11.54 > Shares of Biohaven Ltd. rose by building on their debut surge from the previous day after the company was formally acquired by Pfizer Inc. and spun off.
The clinical-stage biopharmaceutical company and its Nurtec ODT migraine drug were acquired by Pfizer for $11.6 billion in cash and, immediately upon the closing of the acquisition, Biohaven was spun off into a separate entity. Pfizer owns about 3% of the new company.
As part of the acquisition, shareholders of the previous Biohaven received $148.50 a share in cash as well as shares of the new company, which retains the Biohaven moniker and its pipeline of non-calcitonin gene-related peptide programs.
The New Haven, Conn.-based company is launching anew with nearly $258 million in cash and no debt.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
BHVN up 39% @ 11.54 > Shares of Biohaven Ltd. rose by building on their debut surge from the previous day after the company was formally acquired by Pfizer Inc. and spun off.
The clinical-stage biopharmaceutical company and its Nurtec ODT migraine drug were acquired by Pfizer for $11.6 billion in cash and, immediately upon the closing of the acquisition, Biohaven was spun off into a separate entity. Pfizer owns about 3% of the new company.
As part of the acquisition, shareholders of the previous Biohaven received $148.50 a share in cash as well as shares of the new company, which retains the Biohaven moniker and its pipeline of non-calcitonin gene-related peptide programs.
The New Haven, Conn.-based company is launching anew with nearly $258 million in cash and no debt.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
Let's go BHVN !
Closes @ 14.00+ > Company is flush w/ cash and is partners with Pfizer.
Company has no debt.
Merger closes sometime in 2023.
Bounce! Your new porshe's shocks / ball joints are on warranty.
I believe all Doctor's offices, physical therapy centers, patient waiting rooms, hospital ED's , & school nurse's offices will have these Purgo air units.
AERC
Excellent! You are a very good trader!
>>>>> # 62 <<<<<
>>>>> $45,000,000. Revenues this year! <<<<<
The combined company will have the largest range of proprietary and patented, FDA-cleared air purification devices to address the estimated $15 billion, rapidly growing global air purification market. The combined company is expected to generate approximately $45 million of revenues in FY 2022 on a pro forma combined basis and is expected to have a solid balance sheet with a strong liquidity profile upon consummation of the merger.
$$$$$ > Exponential Revenue Growth!
BSFC
New mgmt. team, Molekule CEO, scientists, medical technicians, and field sales engineers providing exponential revenue growth. $olid merger >
AERC
Today we announce that we have signed a definitive agreement to merge with AeroClean Technologies, Inc. (Nasdaq: AERC), a leading air hygiene technology company. The planned merger will unite two leading air purifier brands with a rigorous commitment to science-based technology. This deal underscores the increasing importance of access to clean indoor air for consumers and businesses. As air pollution awareness increases, and more employees return to offices, there is a big demand for indoor air quality services to ensure safer work environments, and together, we believe the combined company will be able to offer even more of this to the world.
As the world grapples with an escalating climate crisis and widespread airborne viruses, the challenge of purifying indoor air is more urgent than ever before. Consumers, government leaders, and business owners understand the urgency of this clean air crisis, yet still struggle to find science-backed solutions. We believe the merger between AeroClean and Molekule signals a new clean air revolution. AeroClean and Molekule have set a high standard in purifier testing, development, and performance—together, the combined brands will seek to complement and supplement each other to improve operational efficiency and increase educational efforts, while expanding clean air access.
The combined company will provide consumers and businesses with access to a broad range of premium, proprietary and patented, FDA-cleared air purifiers on the market. We believe the proposed merger will expedite opportunities for commercial synergies in the B2B space while deepening market penetration and expansion in the healthcare, government, hospitality and education verticals specifically. Furthermore, we believe the combined company will have the balance sheet, liquidity and access to capital to fuel organic growth and pursue additional, value-creating strategic acquisitions within the broader indoor air quality and cleantech space in the future.
So what does this mean for us?
We will be welcoming AeroClean into the Mo family. Their team is relatively small and compliments our business nicely. Operations will continue as usual leading up to the closing of the merger, and there will be a shift to the leadership team in connection with the closing. Upon closing of the proposed transaction, I will transition to Chief Commercial Officer (CCO) and Ronti will become the combined company’s Chief Operating Officer (COO), with AeroClean’s current CEO, Jason DiBona becoming the CEO of the new combined company. AeroClean’s CFO, Ryan Turner, will become our new CFO. I have had the pleasure of getting to know both Jason and Ryan in the recent months and can’t underscore enough how strongly positioned I believe they are to lead this business alongside Ronti and me.
AERC > 4.72
AERC is a great $$$$$ opportunity.
After many months of research and interaction with the FDA, Molekule Air Mini, Air Mini+, Air Pro and Air Pro RX have received FDA 510(k) clearance as a Class II medical device.Nov 18, 2021
Company sucks > Pineapple Holdings (NASDAQ:PEGY) reported quarterly earnings of $0.15 per share. This is a 175 percent increase over losses of $(0.20) per share from the same period last year. The company reported $5.89 million in sales this quarter. This is a 46.43 percent decrease over sales of $11.00 million the same period last year.
Exactly! We will see upcoming contracts and various municipal orders. SOBR revenue stream is one of exponential revenue growth.
SOBR Safe Inc. (Nasdaq:SOBR) is a very interesting device play in the substance detection marketplace. The company has developed a potentially revolutionary touch-based device that instantly detects alcohol levels. It's totally non-invasive and can be deployed to ensure alcohol-induced accidents are entirely prevented in industrial use cases including factory floors, bus fleets, cargo trucking, and other similar applications.
According to company materials, other intended applications include managed care and young drivers. This patent-pending alcohol detection solution helps prevent an intoxicated worker from taking the factory floor; or a driver, the vehicle keys.
SOBR Safe Inc. (Nasdaq:SOBR) most recently announced the closing of a $6 million private placement deal with Aegis Capital Corp. acting as Exclusive Placement Agent.
SOBR management reports that the company issued more than 1.9 million units and 2.1 million pre-funded units at a purchase price of $1.48 a unit. Each unit consists of one share of stock and a non-tradable warrant to buy another share at $1.35. The private placement was priced Sept. 28 and formally closed last Friday. The shares opened at $2.85 on Monday morning and soared from there.
SOBR also recently announced that it has executed on its judicial sales strategy, signing three reseller agreements with national distributors. These agreements provide access to large, established customer networks for the purpose of replacing breathalyzers in the American judicial market following SOBR's recent successes in a leading residential reentry center.
SOBR Safe Inc. (Nasdaq:SOBR) Chairman & CEO Dave Gandini explained, "Distributors are a key force multiplier for SOBRsafe. They have established, trust-based relationships with their customers - all of whom are demonstrated alcohol detection buyers in pursuit of advanced solutions. Our distributors are introducing us to progressive, motivated decision makers, accelerating our market penetration at no fixed cost to SOBRsafe. We look forward to reporting their adoption success to our shareholders."
$ome $weet cranking in AH.
FNGR
The private placement was priced Sept. 28 and formally closed last Friday.
SOBR